BOSTON--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI), a biopharmaceutical company focused on developing novel therapies for prostate cancer and other hormonally driven diseases, today announced a poster presentation outlining the design and rationale for ARMOR3-SV, the planned pivotal Phase 3 trial of galeterone in AR-V7 positive castration-resistant prostate cancer (CRPC) patients, at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2 in Chicago, Illinois.
Help employers find you! Check out all the jobs and post your resume.
